| Course | NUR-6410 Advanced Pharmacology |
|---|---|
| Module | Module 6 |
| Paper type | Prescribing case: prescriptive authority, law and ethics |
| Length | About 1,022 words, 6 pages |
| Format | APA 7 student paper |
| School | Thomas Edison State University |
| Program | Master of Science in Nursing |
| Updated | October 2026 |
Free sample paper for NUR 6410 Module 6
No Waiver, No Wait: Prescriptive Authority, New Jersey Rules and the Ethics of Starting Buprenorphine the Week After an Overdose
Student Name
Master of Science in Nursing, Thomas Edison State University
NUR-6410: Advanced Pharmacology
Mentor Name
Month Day, Year
No Waiver, No Wait: Prescriptive Authority, New Jersey Rules and the Ethics of Starting Buprenorphine the Week After an Overdose
Introduction
Mr. H. is an invented patient, a 31-year-old roofer in Camden who was revived with naloxone by a coworker four days ago after using what he believed was heroin. The emergency department treated him and gave him a naloxone kit and a referral. He comes to the family practice clinic saying he wants to stop using and cannot face withdrawal again. He has used opioids daily for three years after a fall from a ladder led to a prescription that ran out. His last use was 14 hours ago and he is beginning to feel restless and achy. The family nurse practitioner who sees him wants to start buprenorphine today. This paper explains whether she can, under what authority, and what she owes him ethically.
The Evidence for Treating Now
The period after a nonfatal overdose is one of the most dangerous in a person's life. Larochelle et al. (2018) linked state records on survivors of opioid overdose across Massachusetts; in the year after, death from any cause and from opioids was markedly lower among those who received buprenorphine or methadone, yet most survivors received neither. Mattick et al. (2014) pooled the randomized evidence for Cochrane and found that buprenorphine, dosed high enough, holds people in care longer than placebo and cuts their street opioid use. Delay costs lives, so the question of authority is not abstract.
What Changed in 2023
For two decades, prescribing buprenorphine for opioid use disorder required a special federal waiver, often called the X waiver, with training hours, patient limits and a separate identification number. Nurse practitioners gained eligibility only in 2016. Fiscella et al. (2019) argued that these rules kept buprenorphine scarce and stigmatized while methadone clinics and other prescribers faced no comparable barriers for drugs with greater overdose risk. Congress ended it in December 2022 inside the year-end spending bill, and from January 2023 the ordinary DEA number a prescriber already holds, if it covers Schedule III, has been enough federally to treat opioid addiction with buprenorphine, with state rules still on top. A one-time training requirement on substance use disorders now applies to all new or renewing DEA registrants.
What New Jersey Still Requires
Federal law sets the floor, and state law decides who may prescribe and how. A nurse practitioner in New Jersey, whose title there is advanced practice nurse, works from a written joint protocol, signed with a physician partner, that lists the drugs and conditions she manages. To prescribe a controlled substance she needs her own DEA registration and a New Jersey controlled dangerous substance registration, and she must follow state rules on checking the prescription monitoring program. Before starting buprenorphine, she confirms that her joint protocol covers treatment of opioid use disorder, that her registrations include Schedule III and that the clinic has a plan for follow-up visits and urine testing.
| Requirement | Source of the rule |
|---|---|
| DEA registration including Schedule III | Federal |
| Substance use disorder training | Federal, at DEA registration or renewal |
| State controlled dangerous substance registration | New Jersey |
| Written practice agreement (joint protocol) | New Jersey |
| Prescription monitoring program check | New Jersey |
The Induction Plan
Buprenorphine is a partial agonist with high affinity for the mu opioid receptor. Given too soon after a full agonist, it displaces the full agonist and causes precipitated withdrawal, so induction starts when the patient has moderate withdrawal. Fentanyl, which is stored in fat and released slowly, makes timing harder, and some patients need to wait longer or use a lower starting dose. Mr. H. is given buprenorphine-naloxone 2/0.5 milligram films with instructions to begin when his withdrawal is clearly moderate, taking 2 to 4 milligrams and repeating every one to two hours as needed to a first-day total of about 8 milligrams, then 16 milligrams once daily from day two. He leaves with the clinic's after-hours number, a return visit set for Thursday and a fresh naloxone kit.
Ethical Considerations
Informed consent requires that Mr. H. understand the benefits, the risks, including precipitated withdrawal and the danger of combining buprenorphine with alcohol or benzodiazepines, and the alternatives, which include methadone through a licensed program and extended-release naltrexone after withdrawal is complete. Respect for his autonomy means starting the treatment he chooses today rather than requiring counseling first, which current practice no longer demands. Justice asks whether he would have received this care a few years ago; the waiver kept buprenorphine out of many primary care clinics, and those barriers fell hardest on poorer communities like his.
Concerns about diversion are real but should be managed, not used as a reason to deny treatment. People who obtain buprenorphine outside a prescription often say they use it to get through withdrawal when they cannot reach treatment, which suggests that wider access may shrink the demand behind diversion rather than feed it. The combination film with naloxone also discourages injection, since the naloxone becomes active if the film is dissolved and injected. Short initial prescriptions, regular visits, monitoring program checks and honest conversations address them. The prescriber's duty of nonmaleficence includes the harm of withholding an effective treatment from a person at high risk of death.
Documentation and Collaboration
The nurse practitioner documents the diagnosis of opioid use disorder using standard criteria, the monitoring program check, the consent discussion, the induction instructions and the follow-up plan. She informs her collaborating physician under the joint protocol and arranges counseling and support, which Mr. H. may accept when ready. If he develops another condition, such as hepatitis C, the clinic can treat it in the same setting.
Conclusion
Federal law no longer requires a special waiver, so a nurse practitioner with the right DEA registration can start buprenorphine on the day a patient asks. In New Jersey she also needs her state registration and a joint protocol that covers the treatment. The evidence after overdose makes prompt treatment a matter of survival, and the ethical case rests on autonomy, justice and the harm of delay. For Mr. H., legal authority, pharmacology and ethics point to the same decision.
References
Fiscella, K., Wakeman, S. E., & Beletsky, L. (2019). Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry, 76(3), 229-230. https://doi.org/10.1001/jamapsychiatry.2018.3685
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137-145. https://doi.org/10.7326/M17-3107
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2014(2), Article CD002207. https://doi.org/10.1002/14651858.CD002207.pub4
What the NUR 6410 Module 6 instructions ask for
State and federal laws regulating prescriptive practice and the ethics of prescribing run through the whole NUR-6410 course description, and with no public syllabus available this sixth module gathers them into one case. Expect an assignment that asks you to explain the scope of nurse practitioner prescriptive authority in your state, the federal requirements for controlled substances and a legal or ethical dilemma in prescribing. Classrooms often require a specific state, usually the one where you practice, so check whether New Jersey applies to you. Some versions ask for a policy analysis of a change in prescribing law rather than a case. Read the directions for scope and sources, and verify every legal statement against a current source.
How the NUR 6410 Module 6 example is put together
The paper opens with a roofer four days after a fentanyl overdose who asks to start treatment. Mortality evidence after overdose sets the stakes. A section explains the X waiver, the argument against it and its removal in the Consolidated Appropriations Act of 2023, including the new training requirement. New Jersey's requirements follow, with a five-row table separating federal from state rules. The induction plan explains precipitated withdrawal and the difficulty of fentanyl and gives doses and follow-up. An ethics section covers consent, autonomy, justice and diversion, and the paper ends with documentation and collaboration under the joint protocol and a conclusion that ties law, pharmacology and ethics.
Where the marks sit in the NUR 6410 Module 6 rubric
Mentors reading a prescriptive authority paper look first for accurate, current law at both levels, federal and state. Errors such as describing the X waiver as still in force lose significant credit. The legal analysis should be applied to a concrete situation and should separate what federal law permits from what the state requires. Pharmacology still matters: the induction plan should be safe and correctly explained. Ethical reasoning should name principles and apply them to the case rather than listing them. Primary evidence for the clinical stakes, current legal sources and APA formatting complete the work, and documentation details show professional accountability. A line on how the collaborating physician hears about the new treatment, as the joint protocol expects, rounds out the accountability marks.
NUR 6410 Module 6 help: mistakes that cost marks
Legal sections go out of date quickly, and many students still describe the buprenorphine waiver or patient limits that ended in 2023. Check the date of every legal source. Another frequent problem is describing nurse practitioner authority in general terms without naming the state's actual requirements, such as New Jersey's joint protocol. Keep federal and state rules separate. Ethics sections often list principles without applying them; say how each one bears on your decision. Include the pharmacology of the drug you are prescribing, since a legal paper still needs a safe order. If your state is not New Jersey, follow the same structure with its rules. The desk can draft your NUR-6410 authority paper for your state, with the first one free.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Thomas Edison State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More NUR 6410 and Master of Science in Nursing sample papers
- NUR 6410 Module 1: Pharmacokinetics Case: Apixaban Dosing in an 83-Year-Old Woman
- NUR 6410 Module 2: Episodic Prescribing Case: Acute Sinusitis and Antibiotic Stewardship
- NUR 6410 Module 3: Chronic Prescribing Case: Asthma Step-Up to Budesonide-Formoterol
- NUR 6410 Module 4: Pharmacogenomics Case: CYP2C19 and Clopidogrel After a Stent
- NUR 6410 Module 5: Controlled Substances Case: Acute Back Pain, Opioids and a Benzodiazepine
- NUR 5310 Module 5: Implementation Plan
- NUR 5300 Module 3: Randomized Trial Appraisal
- NUR 5290 Module 1: Health Financing Streams Paper
- NUR 5160 Module 6: Comprehensive Encounter Write-Up
NUR 6410 Module 6 questions, answered
Where can I find a free NUR 6410 Module 6 sample paper?
This page holds the complete paper. A nurse practitioner starts buprenorphine for an overdose survivor in New Jersey after the 2023 removal of the federal waiver.
Do nurse practitioners still need an X waiver to prescribe buprenorphine?
No. The waiver ended with a 2023 federal spending law; now an ordinary DEA number covering Schedule III is enough, as long as the state's own rules are met.
What do nurse practitioners need to prescribe controlled substances in New Jersey?
Their own DEA registration, a New Jersey controlled dangerous substance registration and a joint protocol with a collaborating physician that covers the medications prescribed.
What is precipitated withdrawal?
Sudden withdrawal caused when buprenorphine, a high-affinity partial agonist, displaces a full opioid agonist from the receptor. Starting during moderate withdrawal avoids it.
Does buprenorphine reduce deaths after an overdose?
In Massachusetts data on overdose survivors, those who went on to buprenorphine or methadone were far less likely to die in the next year than those who received neither.